Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6092398 | 0.98 | MEN1 (0.50) | MEN1KMT2AOPRD1SLC6A4SIGMAR1 | |
| SCHEMBL24200095 | 0.95 | SPHK2 (0.49) | MEN1KMT2AOPRD1SPHK2SPHK1 | |
| SCHEMBL7272434 | 0.90 | OPRD1 (0.47) | MEN1KMT2AOPRD1SLC6A4SIGMAR1 | |
| SCHEMBL6335780 | 0.87 | OPRD1 (0.52) | OPRD1SPHK2SPHK1 | |
| SCHEMBL1713938 | 0.87 | OPRD1 (0.52) | OPRD1SPHK2SPHK1 | |
| SCHEMBL8414527 | 0.86 | SPHK2 (0.47) | SPHK2SPHK1 | |
| SCHEMBL11969174 | 0.86 | OPRD1 (0.51) | MEN1KMT2AOPRD1SLC6A4SIGMAR1 | |
| SCHEMBL24200047 | 0.86 | OPRD1 (0.51) | OPRD1SIGMAR1SPHK2SPHK1 | |
| SCHEMBL5967865 | 0.86 | OPRD1 (0.51) | MEN1KMT2AOPRD1SLC6A4SIGMAR1 | |
| SCHEMBL10682307 | 0.86 | MEN1 (0.62) | MEN1KMT2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210213010-A1 | TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2021-07-15 | — | — | US | disclosed |
| US-7528147-B2 | Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-05-05 | — | — | US | disclosed |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| EP-1618093-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004094388-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1313711-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| EP-0742216-B1 | Cyclic amide derivatives | EISAI CO LTD (JP) | 2001-11-21 | — | — | EP | disclosed |
| EP-1116716-A1 | Piperidine and piperazine compounds for use in the treatment of Alzheimer | Eisai Co., Ltd. (JP) | 2001-07-18 | — | — | EP | disclosed |
| US-5620976-A | PREVENTION AND TREATMENT OF DISEASES DUE TO INSUFFICIENCY OF THE CENTRAL CHOLINE FUNCTIONS | EISAI CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0742216-A2 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1996-11-13 | — | — | EP | disclosed |
| EP-0742207-A1 | 2-(Indan-1-one-2-yl-alkyl)-1-phenylalkyl-piperidines and processes for their preparation | Eisai Co., Ltd. (JP) | 1996-11-13 | — | — | EP | disclosed |
| US-5521182-A | ACETYLCHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 1996-05-28 | — | — | US | disclosed |
| EP-0677516-A1 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1995-10-18 | — | — | EP | disclosed |
| EP-0673927-A1 | 4-[2-indanyl-1-one]alkylpiperidines as anticholinergic agents | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | disclosed |
| EP-0579263-A1 | 1,4-Substituted piperidines as acetylchozinesterase inhibitors and their use for the treatment of Alzheimer's disease | Eisai Co., Ltd. (JP) | 1994-01-19 | — | — | EP | disclosed |
| US-5100901-A | Treatment of Alzheimer*s disease | EISAI CO., LTD. (JP) | 1992-03-31 | — | — | US | disclosed |
| EP-0468187-A2 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1992-01-29 | — | — | EP | disclosed |
| EP-0296560-A2 | 1,4-Substituted piperidines as acetylcholinesterase inhibitors and their use for the treatment of Alzheimer's disease | Eisai Co., Ltd. (JP) | 1988-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210213010-A1 | TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS | TLR7, TLR9, TLR8 | MEN1 2845/4885KMT2A 699/4885OPRD1 3403/4885 |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | MAP3K19, MAP4K2, MAP3K1 | MEN1 2982/4885KMT2A 1929/4885OPRD1 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.